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Summary 
Macrophage inflammatory protein-1 (MIP) is a recently cloned cytokine that causes neutrophilic 
infiltration and induces an inflammatory response. We studied the effect of MIP-lo~ on histamine 
secretion from basophils and mast cells. Leukocytes from allergic and normal subjects were studied. 
MIP-loe caused dose-dependent release of histamine from basophils of 14 of 20 allergic donors 
at concentrations of 10-9-10 -7 M,  and the mean release  was  13.50  +  2.9%  at the highest 
concentration. In the same experiments, the mean histamine release by anti-immunoglobulin 
E  and  monocyte chemotactic and  activating factor (MCAF)  (10 -7  M)  was  32  +  7%  and 
31  _+ 3%, respectively. The cells from only 2 of 10 normal subjects released histamine in response 
to MIP-loe. Histamine release by MIP-lo~ was rapid, and almost complete within the first 3 rain. 
MIP-lce-induced degranulation was a calcium-dependent noncytotoxic process. MIP-lo~ showed 
chemotactic activity for purified basophils that was comparable to MCAF. Both MIP-lo~ and 
MCAF at 10-7 M concentration elicited a chemotactic response that was 40% of the maximal 
response to CSa (1/zg/ml).  Murine MIP-lo~ induced histamine release from mouse peritoneal 
mast cells in a dose-dependent manner. Thus, we have established that MIP-lo~ is a novel activator 
of basophils  and mast cells. 
I 
ncreased expression of various cytokines has been demon- 
strated in tissue specimens from late phase allergic reac- 
tions (1). Cytokines may play a crucial role in the recruitment 
and activation of inflammatory cells at the site of allergic reac- 
tions.  Cytokines upregulate adhesion molecules on endo- 
thelium and on inflammatory cells such as eosinophils and 
basophils (2). The role of eosinophils in allergic asthma has 
been well established. A growing body of evidence suggests 
that basophils are activated in the late allergic reaction (3). 
Cytokines that activate basophils include IL-3, GM-CSF, and 
connective tissue-activating  peptide III (CTAPIII)/neutrophil- 
activating peptide 2 s (NAP-2) (4, 5). We (6) and others (7) 
have recently demonstrated that monocyte chemotactic and 
activating factor (MCAF)/monocyte chemoattractant protein-1 
(MCP-1) is one of the most potent histamine releasing factors 
(HRF). Histamine releasing activity of MCAF is comparable 
1 Abbreviations used in thispaper: HA, Hepes buffered saline with albumin; 
HACM, Hepes buffered saline with albumin, CaClz, and MgCI2; HCM, 
Hepes buffered saline with CaCh and MgCh; HRF, histamine rdeasing 
factor; MCAF, monocyte chemotactic and  activating factor; MCP-1, 
monocyte chemoattractant protein-I; MIP-lct, macrophage  inflammatory 
protein-lee; and NAP-2, neutrophil-activating peptide 2. 
with that of anti-IgE and FMLP.  Basophils from both al- 
lergic and nonallergic subjects respond to MCAF. We have 
also reported that two other members of the 8-kD family 
of cytokines, namely Ib8  and  RANTES  inhibit  MCAF- 
induced histamine release from basophils (8). MIP-lce is an- 
other member of the 8-kD family of cytokines (9).  In this 
study we show that MIP-lcx induces histamine release from 
basophils and mast cells, and causes chemotaxis of basophils. 
Materiah and Methods 
Reagents.  RPMI 1640 was obtained from Gibco Laboratories 
(Grand Island, NY); human serum albumin, glutamine, Histopaque- 
1077, Con A, penicillin, streptomycin, FMLP, and CSa were from 
Sigma Chemical Co. (St. Louis, MO); Hepes was from Research 
Organics, Inc. (Cleveland, OH); hydroxyethyl starch (HetaStarch) 
was from American McGaw (Irvine, CA); and human and murine 
recombinant MIP-lce was from R & D System, Inc. (Minneapolis, 
MN). Recombinant cytokines were 99% pure by SDS-PAGE and 
RP-HPLC and were received as a lyophilized material in PBS. A 
stock-solution of MIP-lo~ was made at a concentration  of 2  x 
10 -~ M in Hepes buffered saline, pH 7.4, containing 0.3% human 
serum albumin, 2 mM CaC12, and 1 mM MgC12. Affinity-purified 
rabbit anti-human IgE serum (1 mg/ml) was from Behring Diag- 
nostics (Somerville,  NY). Magnetic beads coated with mAb against 
CD2 and CD19 were from Dynal, Inc. (Great Neck,  NY). 
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large group of allergic and nonallergic subjects that were screened 
in our laboratory for histamine release from basophils in response 
to HRF and anti-IrE. Allergic status was defined by the presence 
of clinical  symptoms, past allergic  history, and positive reaction 
to prick skin  testing with a panel of 32 local aeroallergens. 
Venous blood from donors was  anticoagulated with  10 mM 
EDTA and sedimented with 1.5% hydroxyethyl starch for 30 rain 
at room temperature (4). The leukocyte-rich huffy coat was col- 
lected and washed three times in HA buffer (Hepes buffered saline, 
pH 7.4, and 0.03% human serum albumin) in a refrigerated cen- 
trifuge (4~  at 300 g. The washed leukocytes were suspended in 
HACM buffer (Hepes buffered saline, pH 7.4, 0.03% human serum 
albumin, 2 mM CaClz, and I mM MgClz). Leukocytes from 1 ml 
of blood were usually used for one duplicate experiment. 
Purification of Basophils.  For some experiments, basophils were 
purified using a discontinuous Percoll gradient (10). Partially sepa- 
rated  basophils  were  further  purified by  negative  selection  of 
basophils  using mAb (against  CD2 and CD19)-coated magnetic 
beads (11). The final purity of basophils  ranged from 65 to 80%. 
Isolation of Mouse Peritoneal Mast Cells.  DBA/2 mice were used 
to obtain peritoneal mast cells. The peritoneum was lavaged with 
a total of 6 mt of HA buffer.  The cells were washed three times 
with the same buffer and then suspended in HACM. The viability 
of the cells was checked with trypan blue and was >98%.  The 
mast cell content of the peritoneal lavage fluid was <5%. Approx- 
imately 10-20  x  103 mast cells/tube were used for histamine re- 
lease assay. 
Histamine Release Assay.  Aliquots of 50/~l of various dilutions 
of MIP-lce, MCAF, or anti-IgE antibody were incubated with 50 
/zl of leukocyte or mast cell suspension  for 45 rain in a shaking 
water bath at 37~  Each experiment was done in duplicate.  400 
/~1 of HA buffer were added to each tube at the end of the incuba- 
tion. The supernatants were separated from the cells by centrifu- 
gation at 600 g for 5 rain at 4~  The histamine content of the 
supernatants was measured using an automated fluorometric ana- 
lyzer (4). Spontaneous histamine release was assessed by incubating 
the cells in HACM buffer alone.  The total histamine content of 
the cells was measured by lysing the cells with 3% perchloric acid. 
The percentage of histamine release was calculated according to 
the formula: 100 ￿  (histamine in the supernatant/total histamine 
in the cells). Spontaneous histamine release from the cells was usu- 
ally <5%. The values of spontaneous histamine release were sub- 
tracted from the calculated histamine release. 
Chemotaxis of Basophils.  Basophils of 65-80% purity were iso- 
lated as above, and suspended  in Gey's solution. Chemotaxis was  4o - 
carried out in Boyden microchambers using 5/~m polycarbonate  o 
membranes (Nucleopore Corp., Pleasanton, CA). 29 #1 of buffer 
or C5a (1/zg/ml), or various concentrations of MIP-l~ were added  ~ -~  so 
to the lower chamber. Approximately, 10  s basophils  were placed  ~" ~o 
on the top of the membrane. The incubation was carried out for  ~ 
.-  cr~  90 
I h at 37~  in a humidified incubator. The membrane was stained  ~  E 
with Wright's stain. Basophils from twenty fields of duplicate ex-  ~  8 
periments were identified and counted at a magnification of 1,000  ~  ~-  t0 
under immersion oil. 
Results were expressed as mean  +  SEM. Data were analyzed 
for statistical significance using appropriate tests as indicated in the 
text. 
Resuks 
Leukocytes from thirty subjects were studied for histamine 
release by MIP-lot. Twenty subjects were allergic and ten were 
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Figure  1.  Dose-response curves for MlP-lc~-induced histamine release 
from basophils. Leukocytes  from 20 allergic donors were incubated with 
various concentrations of MlP-lc~, and the release of histamine into the 
supernatant was measured spectrofluorometrically.  Results are expressed 
as percent intracellular release (mean  _+  SEM) from 14 responders. 
healthy  subjects.  MIP-lc~  induced  histamine  release from 
basophils of 14 of 20 allergic subjects in a dose-dependent 
manner (Fig.  1).  Human recombinant MCAF and anti-IgE 
were also used in the same experiments. The optimal con- 
centration  of anti-IgE  for inducing  histamine  release was 
1/zg/ml.  The concentration of MCAF  was  10-7 M.  The 
release of histamine by MIP-lot was compared with MCAF 
and anti-IgE (Fig. 2). There was no correlation of histamine 
release between MIP-lot and anti-IgE (r  =  -0.07, P  >0.05 
by Spearman's  rank  correlation),  or between  MIP-lot  and 
MCAF (r  =  -0.3, P >0.05 by Spearman's rank correlation). 
Basophils from six allergic subjects did not respond to MIP- 
lot. Cells from 2 of 10 normal subjects responded to MIP-lot 
with  histamine  release  (6  and  11%  histamine  release  at 
10-7 M).  In three experiments, basophils from three allergic 
donors were purified by discontinuous Percoll gradient cen- 
trifugation and negative selection using anti-CD2 and -CD19 
mAb-coated magnetic beads. The final purity ranged from 
0 
MIP- I  MCAF  ANTI-IGE 
Figure 2.  Comparison  of histamine release  from basophils by MIP-lc~, 
MCAF, and anti-IgE. Leukocytes  from allergic  donors were incubated  with 
MIP-lc~ (10-7 M), MCAF (10-7 M), and anti-lgE (1/~g/ml). Histamine 
was measured as above and expressed as percent release (N = 14 for MIP- 
lot, and N  =  9 for both MCAF and anti-IgE). 
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Figure  3.  MIP-l~e-induced histamine  release from partially  purified 
basophils. Basophils  from three donors were purified  by discontinuous Percoil 
centrifugation followed by negative selection using anti-CD2 and -CD19 
mAb-coated magnetic beads. The final purity ranged from 65 to 80%. 
The results of one of three  similar experiments are shown. 
65 to 80%. MIP-lo~ induced a dose-dependent release of hista- 
mine in these experiments  (Fig.  3). 
The kinetics  of histamine release by MIP-lo~ are shown 
in Fig. 4. The release was very rapid, and over 80% of the 
maximal release took place within 30 s. The release was al- 
most complete within the first 3 min. On the other hand, 
IgE consistently required a lag period of 1-3 rain before any 
noticeable release occurred. 
To investigate whether the degranulation of basophils by 
MIP-loe is a calcium-dependent phenomenon, we conducted 
the experiments in Hepes-albumin buffer in the presence of 
4 mM EDTA containing no calcium or magnesium.  In par- 
allel experiments,  leukocytes were incubated with MIP-lc~ 
in the calcium containing HACM buffer. Anti-IgE was used 
as a positive control in the experiment. The release of hista- 
mine in the absence or presence of calcium and magnesium 
is shown in Fig. 5. There was no histamine release by MIP-lcr 
in the absence of calcium and magnesium. 
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Kinetics  of  Nelease 
The kinetics of MIP-I~ and anti-lgE-induced  histamine re- 
lease from leukocytes.  Leukocytes  from four different donors were incubated 
with MIP-loe (10-7 M) and anti-IgE (10-4 dilution) for different periods 
of time as indicated. At the conclusion ice-cold buffer containing 4 mM 
EDTA was added, and the supernatant was separated by ceatrifugadon 
at 4~  Results of four duplicate experiments are shown. 
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Figure 5.  The effect of calcium depletion on MlP-lcx-induced  hista- 
mine release from  basophils. Leukocytes were washed in cakium- and 
magnesium-free buffer containing  additionally 4 mM EDTA. The washed 
lenkocytes were then incubated with MIP-I~x  (10 -7 M) or anti-IgE (10 -3 
dilution) in the same calcium- and magnesium-free EDTA containing  buffer 
as indicated for histamine release. In parallel  experiments, leukocytes  washed 
in HA buffer were incubated with the agonists in HACM buffer. Results 
of four duplicate experiments are shown. 
Purified basophils were used to study the effect of MIP-lc~ 
on chemotaxis. In the same experiments we investigated the 
chemotactic  activity  of MCAF.  Both MIP-lo~ and MCAF 
induced basophil chemotaxis  in a dose-dependent manner. 
The range of concentration was similar to that required for 
histamine release (Fig. 6). Both MIP-lol and MCAF elicited 
~o40% of the maximal chemotactic response that was induced 
with C5a (1 #g/ml). 
50 
03 
~D  4-0 
-6 
I, 
o  3o 
o.4 
03 
Z  20 
o 
f./) 
o  10 
m 
BUFFER  9  8  7 
(-log  M) 
Figure 6.  Chemotaxis of purified basophils in response to MIP-lcx and 
MCAF. Basophils from four donors were purified by discontinuous Per- 
coil centrifugation followed  by negative selection  using anti-CD2 and -CD19 
mAb-coated magnetic beads. The final purity ranged from 65 to 80%. 
Chemotaxis  with MIP-I~x, MCAF,  or C5a was carried out in Boyden 
microchambers  using 5 #m polycarbonate  membranes. Remits are expressed 
as basophil count per 20 oil fields. The number of cells migrated to CSa 
(1 #g/ml) was 90  _+  4/20 oil fields. 
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Figure 7.  Murine MIP-lo~-induced histamine release from murine peri- 
toneal mast cells. Mouse peritoneum was lavaged with HA buffer and the 
washed cells containing ,~5% mast cells were used in the histamine re- 
lease test.  Results of eight duplicate experiments are shown. 
The effect of murine MIP-lol was studied on mouse peri- 
toneal mast cells. Peritoneal lavage cells containing ",,5% mast 
cells were obtained from DBA/2 mice. MIP-lo~  induced a 
small but significant histamine release from mast cells (Fig. 
7). The response of mouse mast cells to MIP-lc~ was species 
dependent. Initially we tried peritoneal mast cells from BALB/c 
species. MIP-lol failed to induce histamine release from BALB/c 
mast cells. We also studied the effect of murine MIP-lot on 
human basophils and compared with human MIP-lol. Mu- 
fine and human MIP-lc~ induced similar levels of histamine 
release  from human basophils  (Fig.  8). 
Discussion 
MIP-lc~ is a 8.7-kD protein based on amino acid sequence 
and cloning data (9, 12), although it migrates as a 13-15-kD 
protein on SDS-PAGE.  MIP-lc~ belongs  to  the family of 
cytokines so-called intercrine -~ that have four conserved cys- 
teine residues. The first two cystine residues are adjacent. The 
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Figure 8.  Comparison of histamine releasing activity of human and mu- 
rine recombinant MIP-lo~. Leukocytes from three donors were incubated 
with various concentrations of human and murine MIP-lot and the released 
histamine was measured. 
other  members  of this  family  include  MIP-1/~,  MCAF, 
hRANTES, hAct-2h, mJE, and mouse T cell activation gene 
(mTCA) (reviewed in reference 12). Most of these cytokines 
have "~30-70%  sequence homology. 
We have demonstrated that MIP-loL has significant hista- 
mine releasing activity. MIP-lo~ causes histamine release from 
human basophils and mouse mast cells. Its histamine releasing 
capability is  significantly lower than that  of anti-IgE and 
MCAF. However, the true potency of MIP-lc~ is difficult to 
determine because it is a doublet in its natural form, and more 
importantly, it forms 2  x  106 kD multimers as judged by 
SDS-PAGE (12). The multimers can only be resolved at high 
ionic strength. Since the histamine release test is a bioassay 
and is affected by high ionic solutions,  the actual potency 
of MIP-lo~  cannot be assessed using this assay. 
MIP-lo~ causes histamine release from basophils of some 
select allergic donors. In contrast, MCAF causes histamine 
release from basophils of both allergic and normal subjects. 
Previously, we and others (4,  13) have shown that II.-3 and 
GM-CSF cause histamine release from select allergic patients. 
However, a far greater number of donors respond to MIP-loe 
than to IL-3 and GM-CSF. Basophils  from only 3 of the 30 
donors released histamine in response to ID3 and GM-CSF 
in  our laboratory.  Although  the majority of MIP-lo~  re- 
sponders were allergic subjects,  there was no correlation of 
histamine release between MIP-lo~  and anti-IgE. 
Histamine release by MIP-lc~ in a given responder donor 
is reproducible. We repeated the histamine release experiment 
on a group of four people on at least four different occasions 
(original release experiments, kinetics experiments, calcium- 
dependency experiments, purified vs. unpurified basophil ex- 
periments, and human vs. murine MIP-1 experiments), and 
the release by a given concentration of MIP-1 was fairly re- 
producible (+  15%). The reason why basophils from some 
but not all subjects respond to MIP-lol is unclear. It has been 
previously shown that the response of basophils from both 
allergic and normal populations  to secretagogues like C5a 
(14) and anti-IgE (15) is not uniform, and varies from no 
response to extremely good response. Conroy et al. (15) have 
introduced the term "releasability" to emphasize the variable 
intrinsic property of basophils of a given donor to respond 
to different stimuli. They have identified a group of donors 
whose basophils do not respond to anti-IgE and Con A de- 
spite having a significant number of surface IgE molecules. 
It has been postulated that nonreleasing basophils lack an early 
component of the signal transduction pathway (16). It is in- 
teresting that II.-3, a cytokine known for its priming effect 
on basophils,  failed to correct this problem. 
MIP-lol also induces chemotaxis of basophils. Basophils 
from donors who gave a positive response in the histamine 
release assay also responded well in the chemotaxis assay. Many 
secretagogues for basophils have chemotactic activity. In agree- 
ment with the above, we showed that MCAF, a potent secreta- 
gogue for basophils, also has chemotactic activity for basophils. 
MIP-lcz is a strong chemokinetic factor for neutrophils (17). 
We were able to confirm the latter observation in a separate 
set of control experiments (data not shown). 
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lease from basophils and mast cells. Among all the cytokines 
that we have tested thus far, only a few cause histamine re- 
lease from basophils, MCAF being the most potent. We also 
tested human and routine cytokines on human lung and mouse 
peritoneal  mast  cells,  respectively.  All of them,  including 
MCAF, failed to induce histamine release from mast cells (data 
not shown). Murine MIP-lo~ is the only cytokine that was 
found active on mouse peritoneal mast cells. Since there exists 
considerable heterogeneity among mast cells from different 
sources, it is possible that MCAF and other cytokines may 
have activity on mast cells from other anatomical origin, e.g., 
bronchoalveolar mast cells. 
The function of MIP-lc~ is largely unknown. It causes an 
intense  inflammation  when  injected  in  vivo  (17).  The 
infiltrating cells are mostly neutrophils, but there is also an 
increased number of mast cells that occurs within 4 h. MIP- 
lo~ has chemokinetic activity for neutrophils.  The mecha- 
nism  of increased mast cell  numbers is intriguing  and has 
not been investigated. Our report points to another mecha- 
nism of MIP-induced inflammation,  namely, the release  of 
mediators  from basophils and mast ceils. 
MIP-lot may play an important  role in the pathogenesis 
of allergic and nonallergic inflammation Cytokines that have 
histamine releasing activity have been detected in the blister 
fluid from late phase cutaneous allergic reactions (18), bron- 
choalveolar lavage fluid (19), and nasal washings (20). Increased 
synthesis of HRF by mononuclear cells has been reported 
in asthma (21) and atopic dermatitis with food allergy (22). 
Also, increased levels of HRF-like activity have been detected 
in bronchoalveolar lavage fluid from patients with pulmo- 
nary fibrosis (23), and in skin chamber fluid from patients 
with urticaria (24). The individual contribution of MIP-lot 
to the activity of the crude biological fluid will have to be 
determined in the future to assess the exact role played by 
these cytokines in human  illnesses. 
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